Clariant delivers good start to 2024 with improved profitability –
outlook confirmed
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Q1 2024
sales decreased by 6 % organically in local
currencies1 to CHF
1.014 billion against a strong comparison base in Q1 2023, driven
by stabilized volumes and lower pricing
- Q1 2024
EBITDA margin improved to 17.1 % compared to 13.9 % in Q1
2023, driven by performance programs, deflationary raw material and
energy price trends, strong margin in aviation, and reduced
sunliquid®
impact
- Closing of
Lucas Meyer Cosmetics acquisition on 2 April 2024 strengthens
position as a true specialty chemical company and expands
Clariant’s reach into attractive cosmetic ingredients
space
- Confirmed
Outlook 2024 and medium-term targets
“Clariant delivered a good start to the year in the first quarter
of 2024 demonstrating the resilience of our specialty chemicals
portfolio. The improved profitability was driven by our performance
programs and successful margin management in the deflationary
environment. Our topline performance reflected stabilized volumes
and lower pricing against a strong comparison base last year.
Sequentially, we saw limited restocking activities from customers,
although uncertainties about underlying demand remain. The lower
sunliquid® impact and strong margin in our aviation
business positively contributed to profitability. We are on track
to deliver on our 2024 guidance and remain committed toward our
medium-term targets,” said Conrad Keijzer, Chief Executive Officer
of Clariant.
“We recently closed the acquisition of Lucas
Meyer Cosmetics, opening a new chapter for Clariant. I warmly
welcome our new team members, and together we are looking forward
to the growth opportunities that lie ahead. In addition, we
achieved a significant safety milestone recording zero accidents in
the month of March, equating to approximately two million working
hours without accidents across all of our 73 production sites,
offices, laboratories and warehouses worldwide. This achievement is
a direct result of the proactive measures we have implemented to
promote a safe workplace for our employees. We have set the right
trajectory internally as well as externally to deliver on our
targets,” Conrad Keijzer added.
Business Summary
|
|
First Quarter |
in CHF million |
|
|
|
|
2024 |
2023 |
% CHF |
% LC(1) |
Sales |
|
|
|
|
1 014 |
1 200 |
- 16 |
- 11 |
EBITDA |
|
|
|
|
173 |
167 |
4 |
|
- margin |
|
|
|
|
17.1 % |
13.9 % |
|
|
EBITDA before exceptional items |
|
|
|
|
184 |
184 |
0 |
|
- margin |
|
|
|
|
18.1 % |
15.3 % |
|
|
Sales bridge: |
|
Price - 5 %; Volume - 1 %; Currency - 5 %; Scope
- 5 % |
(1) Excluding
hyperinflation accounting countries Argentina and Türkiye
1 All references to local currency growth, pricing,
volumes, and scope exclude the impact from hyperinflation countries
Argentina and Türkiye. All references to currency include a net
impact from hyperinflation countries Argentina and Türkiye.
First Quarter 2024 Group
Discussion
MUTTENZ, 30
APRIL 2024
Clariant, a sustainability-focused specialty
chemical company, today announced first quarter 2024 sales of
CHF 1.014 billion, down 6 % organically in local
currency1 and 11 % including scope in local
currency (16 % in Swiss francs) versus Q1 2023. Pricing
decreased by 5 % year-on-year and volumes by 1 %. Changes
in scope had a negative impact of 5 % due to the divestments
of the North American Land Oil and Quats businesses.
Care Chemicals sales decreased by 4 %
organically in local currency and 9 % related to scope versus
Q1 2023. Sales in Mining Solutions, Industrial Applications and
Personal & Home Care grew organically while the seasonal
aviation business declined, due to less favorable weather impacting
volume and lower formula-based prices. Sequentially, volumes
increased by 5 % in the first quarter, partially driven by
limited customer restocking from low inventory levels at year-end
2023. Catalysts sales declined modestly by 2 % in local
currency, with growth in Syngas & Fuels and Propylene offset by
Ethylene and Specialties due to the normal project cycle of the
business. Adsorbents & Additives sales decreased by 11 %
in local currency against a high comparison base in Q1 2023 due to
challenges in key end markets for the Additives segments, despite
limited sequential customer restocking activities.
In the first quarter, local currency sales in
the Europe, Middle East, and Africa region were down 16 %
(3 % related to scope) versus Q1 2023, with declines in all
businesses as economic activity in the region remained muted. Sales
in the Americas grew organically by 4 %, driven by stronger volumes
in Care Chemicals and Catalysts. Including scope (- 11 %), sales in
the region declined by 7 % in local currency. Sales in Asia-Pacific
were down 6 % (2 % related to scope) in local currency,
mitigated by organic growth in China of 5 %, driven by Care
Chemicals and Adsorbents and Additives.
Group EBITDA increased by 4 % to
CHF 173 million, with the corresponding margin of
17.1 % significantly above the 13.9 % margin reported in
the first quarter of 2023. Cost savings from performance programs
of approximately CHF 11 million contributed positively to
offset inflation. Lower cost trends in raw materials
(- 12 %) and energy (- 22 %, driven by Europe)
positively supported profitability in all businesses despite lower
pricing. Strong margin in the seasonal aviation business also
positively contributed to profitability. The Group incurred a total
CHF 5 million negative operational impact from the
sunliquid® bioethanol activities, which represented an
improvement against the CHF 13 million negative
operational impact of the prior year. As announced in December
2023, Clariant is ceasing operations at the plant in Romania and is
downsizing related activities of the Business Segment Biofuels
& Derivatives in Germany. The previous year figure was also
negatively impacted by a CHF 11 million one-off fair
value adjustment on the Heubach Group participation. Restructuring
expenses totaled CHF 7 million, mainly related to the
Additives segments. Underlying profitability, as reflected by
EBITDA before exceptional items, of CHF 184 million was
flat year on year and increased sequentially by 17 %,
representing an improved underlying margin of 18.1 % compared
to 15.3 % in the prior year and 14.9 % in the prior
quarter.
1 All references to local currency growth, pricing, volumes,
and scope exclude the impact from hyperinflation countries
Argentina and Türkiye. All references to currency include a net
impact from hyperinflation countries Argentina and Türkiye.
ESG Update – Leading in sustainability
and safety
Clariant’s Scope 1 and 2 total greenhouse gas
emissions fell to 0.52 million tons in the last twelve months
(April 2023 to March 2024), a decline of 4 % from
0.54 million tons in the full year 2023. The total indirect
greenhouse gas emissions for purchased goods and services (Scope 3)
also decreased by 5 %, from 2.28 million tons in the full
year 2023 to 2.16 million tons in the last twelve months.
These results demonstrate continued progress toward reaching the
Group’s 2030 emissions reduction targets.
Clariant achieved a major safety milestone,
recording zero DART (Days Away, Restricted, or Transferred) cases
in March, equating to approximately 2 000 000 working
hours without accidents across all of its 73 production sites,
offices, laboratories, and warehouses worldwide. This achievement
underscores the commitment of all our colleagues to making safety a
top priority every day and is a testament to the effectiveness of
Clariant’s comprehensive safety protocols and initiatives. Clariant
remains steadfast in its commitment to promote a safe and healthy
workplace for all its employees. In the first quarter of 2024, the
DART rate remained unchanged at 0.21, as observed at year-end
2023.
Outlook confirmed
For the full year 2024, Clariant expects to see a
continued easing of the inflationary environment but no significant
economic recovery, with macroeconomic uncertainties and risks
remaining. Clariant therefore reiterates its expectations for low
single-digit sales growth in local currency. Growth in Care
Chemicals, including the impact of the acquisition of Lucas Meyer
Cosmetics, and in Adsorbents & Additives is expected to offset
a temporary slowdown in Catalysts momentum. Reported EBITDA margin
is expected to improve to around 15 %. This includes the
impact of the Lucas Meyer Cosmetics acquisition and a
sunliquid® restructuring/exceptional impact of up to
CHF 30 million. Clariant also expects operational
sunliquid® costs of up to CHF 15 million
related to preparation for the closure or divestment of the Podari
plant. EBITDA margin excluding the operational and exceptional
sunliquid® impacts is expected at around 16 %. Cost
savings benefits from restructuring programs are expected to
deliver CHF 28 million in 2024.
Clariant reiterates its expectation that 2025
will be a year of continued, albeit significant, recovery in
profitability. In 2025, on the basis of an expected 3 – 5 %
improvement in key end market demand, Clariant expects to achieve
EBITDA margin of 17 – 18 %, and free cash flow conversion at
the targeted level of around 40 %. Clariant remains committed
to its medium-term targets as end markets recover and growth
normalizes over the next two to three years. Clariant will adopt an
agile response to the economic environment and remain resolute in
its plans to achieve the medium-term targets. The company is well
positioned to achieve these targets as the accretive impacts of the
Lucas Meyer Cosmetics acquisition and investments in China are
realized. In addition, benefits from increased cost savings are
expected.
Business Discussion
Business Unit Care
Chemicals
|
|
First Quarter |
in CHF million |
|
|
|
|
2024 |
2023 |
% CHF |
% LC(1) |
Sales |
|
|
|
|
581 |
703 |
- 17 |
- 13 |
EBITDA |
|
|
|
|
123 |
128 |
- 4 |
|
- margin |
|
|
|
|
21.2 % |
18.2 % |
|
|
EBITDA before exceptional items |
|
|
|
|
125 |
130 |
- 4 |
|
- margin |
|
|
|
|
21.5 % |
18.5 % |
|
|
(1) Excluding
hyperinflation accounting countries Argentina and Türkiye
Sales
In the first quarter of 2024, sales in the
Business Unit Care Chemicals decreased by 4 % organically in
local currency and by 13 % including scope in local currency
(17 % in Swiss francs) versus Q1 2023. Volumes in the first
quarter were up 2 %, supported by limited customer restocking
in Industrial Applications and Personal & Home Care, while
pricing decreased by 6 % compared to Q1 2023, mainly due to
formula-based price adjustments on lower feedstock levels from
previous year. On a sequential basis, sales increased by 4 %
in local currency, driven by a 5 % increase in volumes
(restocking) despite slightly lower pricing.
Organic growth in Mining Solutions, Industrial
Applications, and Personal & Home Care was driven by positive
volumes, while Oil Services was flat when excluding the divestment
impact. Base Chemicals declined due to lower aviation sales, while
in Crop Solutions weak demand and destocking across the entire
supply chain continued.
Care Chemicals sales in Europe, Middle East, and
Africa decreased at a mid-teens percentage rate organically, with
the decrease in pricing slightly more pronounced than volumes. In
the Americas, sales were up by a mid-single-digit percentage rate
organically as volume growth more than offset lower pricing. Sales
in Asia-Pacific increased by a low-single digit percentage rate
organically, mainly attributable to stronger volumes across the
region, and China in particular.
EBITDA Margin
In the first quarter, the EBITDA margin
increased to 21.2 % versus 18.2 % in the same period last
year due to decreasing raw material and energy costs, combined with
successful margin management, the positive impact from performance
programs, and strong profitability in the seasonal businesses. On a
sequential basis, Care Chemicals recorded a 12 % increase in
EBITDA to CHF 123 million, representing an EBITDA margin
of 21.2 % compared to 20.0 % in the prior quarter, driven
by higher volumes (+ 5 %) and the deflationary
environment.
Care Chemicals Insight
With the unveiling of CycloRetin™, a natural
skincare active derived from Prince Ginseng, Clariant provides its
customers in the personal care industry with a new,
high-performing, eco-friendly alternative to traditional retinol.
This follows extensive testing of the benefits of cyclic peptides,
which are known to positively impact the appearance of the skin.
Prince Ginseng was discovered to have outstanding potential to
restart the skin matrix production cycle, improving collagen and
reducing signs of aging, providing comparable efficacy to retinol
and bakuchiol. At the in-cosmetics 2024 trade show, Clariant
showcased two formulations containing CycloRetin™, Firming Mask and
Mask Mist, offering efficient skincare solutions that were well
received by industry representatives.
Business Unit Catalysts
|
|
First Quarter |
in CHF million |
|
|
|
|
2024 |
2023 |
% CHF |
% LC(1) |
Sales |
|
|
|
|
187 |
205 |
- 9 |
- 2 |
EBITDA |
|
|
|
|
25 |
13 |
92 |
|
- margin |
|
|
|
|
13.4 % |
6.3 % |
|
|
EBITDA before exceptional items |
|
|
|
|
24 |
13 |
85 |
|
- margin |
|
|
|
|
12.8 % |
6.3 % |
|
|
(1) Excluding
hyperinflation accounting countries Argentina and Türkiye
Sales
In the first quarter of 2024, sales in the
Business Unit Catalysts declined by 2 % in local currency
(9 % in Swiss francs). Volumes declined by 2 % versus Q1
2023 due to the project nature of the business, while pricing was
flat. Sales in Syngas & Fuels grew at a mid-twenties percentage
rate and at a mid-teen percentage rate in Propylene. The remaining
segments declined, with the most pronounced in Ethylene. On a
quarterly sequential basis, sales were down 27 % in local
currency due to the typical seasonality at the start of the year
impacting volumes, while pricing was flat.
Catalysts sales declined at a low-teen
percentage rate in the Europe, Middle East, and Africa region due
to the project cycle of the business, with Europe recording a
decline in sales, while the Middle East and Africa were flat. Sales
in the Americas increased at a mid-sixties percentage rate,
primarily driven by Syngas & Fuels. In Asia-Pacific, the
largest geographic market, sales declined at a low-teen percentage
rate, with a slightly less pronounced decline in China, due to a
normalization of growth projects in comparison to last year.
EBITDA Margin
In the first quarter, the EBITDA margin
increased to 13.4 % from 6.3 % in Q1 2023, mainly due to
a CHF 8 million improvement of the negative operational
impact from sunliquid® and stable pricing in a
deflationary environment. Excluding the sunliquid®
impact, the EBITDA margin was 16.1 %, a 320-basis point
improvement over the 12.9 % recorded in the first quarter of
2023. Sequentially, EBITDA before exceptional items, which allows a
like-for-like comparison by excluding the exceptional items booked
in Q4 2023 related to the sunliquid® decision, decreased
by 41 % to CHF 24 million, representing an underlying
margin of 12.8 % compared to 15.9 % in the prior quarter.
This is the result of the typical seasonal volume patterns in the
first quarter compared to the final quarter of the year, and the
respective impact on operating leverage.
Catalysts Insight
Clariant’s CATOFIN® catalyst,
together with process technology provided by process partner Lummus
Technology, was selected by Huizhou Boeko Materials Co. Ltd for the
dehydrogenation of isobutane at the new plant in Huizhou City,
China. Once complete, this plant will produce 550 000 metric tons
per annum (MTA) of net isobutylene, which will serve as feedstock
for the downstream production of methyl tertiary butyl ether
(MTBE).
The highly efficient CATOFIN has proven to be a
popular choice for China’s chemical industry. Since its commercial
launch in 2017, the catalyst has been selected for 39 new projects
around the world and more than 50 % of these plants are
located in China. The recently opened CATOFIN catalyst plant with
significant production capacity in Jiaxing, Zhejiang Province,
ensures localized production for Clariant’s regional customers as
well as proximity for technical support and services.
Business Unit Adsorbents &
Additives
|
|
First Quarter |
in CHF million |
|
|
|
|
2024 |
2023 |
% CHF |
% LC(1) |
Sales |
|
|
|
|
246 |
292 |
- 16 |
-11 |
EBITDA |
|
|
|
|
36 |
54 |
- 33 |
|
- margin |
|
|
|
|
14.6 % |
18.5 % |
|
|
EBITDA before exceptional items |
|
|
|
|
46 |
55 |
- 16 |
|
- margin |
|
|
|
|
18.7 % |
18.8 % |
|
|
(1) Excluding
hyperinflation accounting countries Argentina and Türkiye
Sales
In the first quarter of 2024, sales in the
Business Unit Adsorbents & Additives decreased by 11 %
organically in local currency (16 % in Swiss francs). In the
Adsorbents segments, sales declined by a low single-digit
percentage rate, as positive pricing did not offset lower volumes.
In the Additives segments, sales declined by a high-teens
percentage rate, primarily due to lower volumes with weak demand in
key end markets compared to prior year levels. In the Business
Unit, pricing declined by 4 % against a high comparison base
in Q1 2023. On a quarterly sequential basis, sales in the Business
Unit decreased by 2 % in local currency, equally balanced
between volumes and pricing. Market conditions for the Additives
segments stabilized, and limited customers restocked from low
inventory levels at year-end.
In Europe, Middle East, and Africa, the largest
region, sales decreased by a low-teens percentage rate, as growth
in Adsorbents did not offset lower sales in the Additives segments.
In the Americas, sales declined at a mid-teens percentage rate,
with a more pronounced decline in Additives. While Asia-Pacific
sales were down at mid-single-digit percentage rate, China sales
grew at a low-teens percentage rate due to a positive quarter in
Additives.
EBITDA Margin
In the first quarter, the EBITDA margin
decreased to 14.6 % from 18.5 % in Q1 2023. Profitability
levels were impacted by restructuring charges of
CHF 9 million in Additives and business mix. EBITDA
margin before exceptional items was flat at 18.7 % (vs.
18.8 % in Q1 2023). Sequentially, EBITDA margin before
exceptional items increased by 119 % to
CHF 46 million, representing an underlying margin
improvement from 8.2 % to 18.7 %. The sequential increase
was driven by operating leverage (limited restocking in the
Additives segments) and lower raw material and energy costs, as
well as supported by the structural improvement efforts initiated
during the prior year.
Adsorbents & Additives
Insight
At NPE2024, the largest plastics trade show in
the Americas, Clariant will showcase its latest additive solutions
that deliver on both performance and sustainability to participants
from automotive to packaging and consumer products to construction.
This includes Clariant’s Licocare® RBW Vita waxes, which
are based on renewable bio-based rice bran wax feedstocks and
provide superior performance. This makes them a natural replacement
for traditional coal-based montan waxes for use in engineering
polymers.
Furthermore, the company will present its
AddWorks® line, which is a portfolio of additive
solutions for the plastics industry to address technical challenges
including light, thermal, and process stabilization, as well as the
Exolit® OP range of high-performance, halogen-free flame
retardants. By combining innovation and sustainability criteria,
Clariant provides solutions that are safe and more sustainable by
design, have leading performance, and tackle some of the most
pressing environmental challenges.
Q1 2024 Media Release EN
CORPORATE MEDIA RELATIONS
Jochen Dubiel
Phone +41 61 469 63 63
jochen.dubiel@clariant.com
Ellese Caruana
Phone +41 61 469 63 63
ellese.caruana@clariant.com
Luca Lavina
Phone +41 61 469 63 63
luca.lavina@clariant.com
Follow us on X, Facebook, LinkedIn, Instagram. |
INVESTOR RELATIONS
Andreas Schwarzwälder
Phone +41 61 469 63 73
andreas.schwarzwaelder@clariant.com
Thijs Bouwens
Phone +41 61 469 63 73
thijs.bouwens@clariant.com
|
This media release contains certain statements that are neither
reported financial results nor other historical information. This
document also includes forward-looking statements. Because these
forward-looking statements are subject to risks and uncertainties,
actual future results may differ materially from those expressed in
or implied by the statements. Many of these risks and uncertainties
relate to factors that are beyond Clariant’s ability to control or
estimate precisely, such as future market conditions, currency
fluctuations, the behavior of other market participants, the
actions of governmental regulators and other risk factors such as:
the timing and strength of new product offerings; pricing
strategies of competitors; the company’s ability to continue to
receive adequate products from its vendors on acceptable terms, or
at all, and to continue to obtain sufficient financing to meet its
liquidity needs; and changes in the political, social and
regulatory framework in which the Company operates or in economic
or technological trends or conditions, including currency
fluctuations, inflation and consumer confidence, on a global,
regional or national basis. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this document. Clariant does not undertake
any obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of these materials.
www.clariant.com
Clariant is a focused specialty chemical company led by the
overarching purpose of ‘Greater chemistry – between people and
planet’. By connecting customer focus, innovation, and people the
company creates solutions to foster sustainability in different
industries. On 31 December 2023, Clariant totaled a staff number of
10 481 and recorded sales of CHF 4.377 billion in the fiscal year
for its continuing businesses. As of January 2023, the Group
conducts its business through the three Business Units Care
Chemicals, Catalysts, and Adsorbents & Additives. Clariant is
based in Switzerland. |
Clariant (LSE:0QJS)
Historical Stock Chart
From Jan 2025 to Mar 2025
Clariant (LSE:0QJS)
Historical Stock Chart
From Feb 2024 to Mar 2025